Gene · 1143
CHRNB4: cholinergic receptor nicotinic beta 4 subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRNB4: cholinergic receptor nicotinic beta 4 subunit. Genes, record 1143. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1143
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30926 | Neuronal acetylcholine receptor subunit beta-4 | 498 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41250 | P30926 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1951 | P30926 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1535 | P30926 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 943 | P30926 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 943 | P30926 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1535 | P30926 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1951 | P30926 | Espacenet |
| EP 4551941 A2 | 2025-05-14 | 46 | P30926 | Espacenet |
| JP 2024516159 A | 2024-04-12 | 2 | P30926 | Espacenet |
| KR 1020240000561 A | 2024-01-02 | 2 | P30926 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASM-024 | CHEMBL3707249 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist | ANTAGONIST | ChEMBL |
| LARAZOTIDE | CHEMBL2105646 | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist | PARTIAL AGONIST | ChEMBL |
| LARAZOTIDE ACETATE | CHEMBL2103815 | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist | PARTIAL AGONIST | ChEMBL |
| MECAMYLAMINE | CHEMBL267936 | Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
| MECAMYLAMINE HYDROCHLORIDE | CHEMBL1237082 | Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
| PENTOLINIUM | CHEMBL1271 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist | ANTAGONIST | ChEMBL |
| PENTOLINIUM TARTRATE | CHEMBL1318287 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist | ANTAGONIST | ChEMBL |
| SIMPINICLINE | CHEMBL4594254 | Neuronal acetylcholine receptor; alpha3/beta4 agonist | AGONIST | ChEMBL |
| TRIMETHAPHAN | CHEMBL1201329 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist | ANTAGONIST | ChEMBL |
| TRIMETHAPHAN CAMSYLATE | CHEMBL1245 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist | ANTAGONIST | ChEMBL |
Trials29
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05747534 | LARAZOTIDE | PHASE2 | ClinicalTrials.gov | |
| NCT05022303 | LARAZOTIDE ACETATE | PHASE2 | ClinicalTrials.gov | |
| NCT03633461 | SIMPINICLINE | PHASE2 | 2022-02-03 | ClinicalTrials.gov |
| NCT03452397 | SIMPINICLINE | PHASE2 | 2021-12-14 | ClinicalTrials.gov |
| NCT03244488 | MECAMYLAMINE | ClinicalTrials.gov | ||
| NCT02726711 | TRIMETHAPHAN | PHASE1 | ClinicalTrials.gov | |
| NCT02187094 | SIMPINICLINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT01855230 | ASM-024 | PHASE2 | ClinicalTrials.gov | |
| NCT01396213 | LARAZOTIDE ACETATE | PHASE2 | ClinicalTrials.gov | |
| NCT01190826 | ASM-024 | PHASE2 | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsNIH grants1,451
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRNB4 papers | Newest fiscal year |
|---|---|---|---|
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 23 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 9 | 2025 |
| R35CA197449 | Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer Research | 9 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 8 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 7 | 2025 |
| P50AA012870 | Center for the Translational Neuroscience of Alcoholism | 7 | 2025 |
| U01CA164973 | Understanding Population Differences in Cancer: The MEC Study | 5 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,451Source NIH's project files
See all 1,451 nih grantsPapers807
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated multi-omics analysis reveals gut microbiota-associated placental metabolic and transcriptomic alterations in placenta previa. | mSystems | 2026 | 42454935 | PubTator, text mining | PubMed |
| Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer. | Clin Genitourin Cancer | 2026 | 42236361 | PubTator, text mining | PubMed |
| CHRNB4-Mediated Neuroactive Signaling Rewiring Drives Adaptive Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia. | Cancers (Basel) | 2026 | 42073514 | PubTator, text mining | PubMed |
| Exploring the shared genetic architecture between periodontitis and cardiovascular disease. | BDJ Open | 2026 | 41916952 | PubTator, text mining | PubMed |
| Molecular signatures and causal factors underlying latent cytomegalovirus infection among people living with HIV (PLHIV). | Nat Commun | 2026 | 41881997 | PubTator, text mining | PubMed |
| Rare coding variants in CHRNB3 associate with reduced daily cigarette smoking across ancestries. | Nat Commun | 2026 | 41735279 | PubTator, text mining | PubMed |
| Rewired Neuroactive Ligand-Receptor Signaling Confers Adaptive Resistance to BCL-2 Inhibition in AML. | Res Sq | 2026 | 41646400 | PubTator, text mining | PubMed |
| Genetic risk factors for pneumonia differ by patient subgroup. | EBioMedicine | 2026 | 41579494 | PubTator, text mining | PubMed |
| Association of SNPs in nAChRs genes, areca nut chewing and smoking, and their interaction with lung cancer in Hainan, China: a case control study. | BMC Cancer | 2025 | 40197297 | PubTator, text mining | PubMed |
| fastGxE: Powering genome-wide detection of genotype-environment interactions in biobank studies. | Res Sq | 2025 | 40166017 | PubTator, text mining | PubMed |
1 to 10 of 807
See all 807 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1143
GET https://conductscience.org/api/genes/v1/1143/patents?page=2